Published in Eur Heart J on November 23, 2012
Prevalence, incidence and clinical impact of cachexia: facts and numbers-update 2014. J Cachexia Sarcopenia Muscle (2014) 1.68
Prevalence, incidence, and clinical impact of sarcopenia: facts, numbers, and epidemiology-update 2014. J Cachexia Sarcopenia Muscle (2014) 1.50
From muscle wasting to sarcopenia and myopenia: update 2012. J Cachexia Sarcopenia Muscle (2012) 1.23
Exercise intolerance in heart failure with preserved ejection fraction: more than a heart problem. J Geriatr Cardiol (2015) 0.95
Highlights of mechanistic and therapeutic cachexia and sarcopenia research 2010 to 2012 and their relevance for cardiology. Arch Med Sci (2013) 0.85
The 'skeletal muscle hypothesis in heart failure' revised. Eur Heart J (2013) 0.82
The regulation of muscle mass by endogenous glucocorticoids. Front Physiol (2015) 0.81
Frailty in Advanced Heart Failure: A Consequence of Aging or a Separate Entity? Clin Med Insights Cardiol (2015) 0.81
Sarcopenic obesity and the pathogenesis of exercise intolerance in heart failure with preserved ejection fraction. Curr Heart Fail Rep (2015) 0.80
Nutritional status and its effects on muscle wasting in patients with chronic heart failure: insights from Studies Investigating Co-morbidities Aggravating Heart Failure. Wien Klin Wochenschr (2016) 0.79
Reduced skeletal muscle oxidative capacity and impaired training adaptations in heart failure. Physiol Rep (2015) 0.78
Clinical utility of exercise training in heart failure with reduced and preserved ejection fraction. Clin Med Insights Cardiol (2015) 0.78
Creatinine excretion rate, a marker of muscle mass, is related to clinical outcome in patients with chronic systolic heart failure. Clin Res Cardiol (2014) 0.78
Publication trends in cachexia and sarcopenia in elderly heart failure patients. Wien Klin Wochenschr (2016) 0.78
Muscle wasting and cachexia in heart failure: mechanisms and therapies. Nat Rev Cardiol (2017) 0.78
Cardiac cachexia: hic et nunc. J Cachexia Sarcopenia Muscle (2016) 0.78
Fetuin-A as a predicator of sarcopenic left ventricular dysfunction. Sci Rep (2015) 0.77
Effect of exercise-based cardiac rehabilitation on non-culprit mild coronary plaques in the culprit coronary artery of patients with acute coronary syndrome. Heart Vessels (2015) 0.76
New Approaches to Treating Cardiac Cachexia in the Older Patient. Curr Cardiovasc Risk Rep (2013) 0.76
Skeletal muscle aging: influence of oxidative stress and physical exercise. Oncotarget (2017) 0.76
Ghrelin and hormonal markers under exercise training in patients with heart failure with preserved ejection fraction: results from the Ex-DHF pilot study. ESC Heart Fail (2016) 0.75
Sarcopenia in heart failure: mechanisms and therapeutic strategies. J Geriatr Cardiol (2016) 0.75
Cardiac Cachexia: Perspectives for Prevention and Treatment. Arq Bras Cardiol (2016) 0.75
Primary skeletal muscle myoblasts from chronic heart failure patients exhibit loss of anti-inflammatory and proliferative activity. BMC Cardiovasc Disord (2016) 0.75
Relationship between adductor pollicis muscle thickness and subjective global assessment in a cardiac intensive care unit. Rev Bras Ter Intensiva (2016) 0.75
Serum vitamin D, intact parathyroid hormone, and Fetuin A concentrations were associated with geriatric sarcopenia and cardiac hypertrophy. Sci Rep (2017) 0.75
Cardiac Resynchronization Therapy Leads to Improvements in Handgrip Strength. Cardiol Res (2016) 0.75
Muscle wasting is associated with reduced exercise capacity and advanced disease in patients with chronic heart failure. Future Cardiol (2013) 0.75
Muscle size explains low passive skeletal muscle force in heart failure patients. PeerJ (2016) 0.75
Peripheral reflex feedbacks in chronic heart failure: Is it time for a direct treatment? World J Cardiol (2015) 0.75
Effect of tighter glycemic control on cardiac function, exercise capacity, and muscle strength in heart failure patients with type 2 diabetes: a randomized study. BMJ Open Diabetes Res Care (2016) 0.75
Muscle wasting in heart failure : The role of nutrition. Wien Klin Wochenschr (2016) 0.75
Skeletal muscle alterations in HFrEF vs. HFpEF. Curr Heart Fail Rep (2017) 0.75
Randomised feasibility trial into the effects of low-frequency electrical muscle stimulation in advanced heart failure patients. BMJ Open (2017) 0.75
An exploratory study on the efficacy and safety of a BCAA preparation used in combination with cardiac rehabilitation for patients with chronic heart failure. BMC Cardiovasc Disord (2017) 0.75
2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J (2013) 12.73
Definition and classification of cancer cachexia: an international consensus. Lancet Oncol (2011) 7.78
Warfarin and aspirin in patients with heart failure and sinus rhythm. N Engl J Med (2012) 6.60
The Seattle Heart Failure Model: prediction of survival in heart failure. Circulation (2006) 6.58
Frailty consensus: a call to action. J Am Med Dir Assoc (2013) 6.54
Clinical Features and Outcomes of Takotsubo (Stress) Cardiomyopathy. N Engl J Med (2015) 6.00
Cachexia: a new definition. Clin Nutr (2008) 5.49
A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J Am Coll Cardiol (2013) 5.04
Uric acid and survival in chronic heart failure: validation and application in metabolic, functional, and hemodynamic staging. Circulation (2003) 3.89
Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J (2005) 3.89
Utility of Doppler echocardiography and tissue Doppler imaging in the estimation of diastolic function in heart failure with normal ejection fraction: a comparative Doppler-conductance catheterization study. Circulation (2007) 3.76
Results of a non-specific immunomodulation therapy in chronic heart failure (ACCLAIM trial): a placebo-controlled randomised trial. Lancet (2008) 3.71
Role of left ventricular stiffness in heart failure with normal ejection fraction. Circulation (2008) 3.56
Cardio-renal syndromes: report from the consensus conference of the acute dialysis quality initiative. Eur Heart J (2009) 3.52
Digoxin reduces 30-day all-cause hospital admission in older patients with chronic systolic heart failure. Am J Med (2013) 3.46
State of the art: using natriuretic peptide levels in clinical practice. Eur J Heart Fail (2008) 3.35
State of the science: promoting self-care in persons with heart failure: a scientific statement from the American Heart Association. Circulation (2009) 3.05
The effect of micronutrient supplementation on quality-of-life and left ventricular function in elderly patients with chronic heart failure. Eur Heart J (2005) 2.92
Impact of remote telemedical management on mortality and hospitalizations in ambulatory patients with chronic heart failure: the telemedical interventional monitoring in heart failure study. Circulation (2011) 2.87
Effects of xanthine oxidase inhibition with allopurinol on endothelial function and peripheral blood flow in hyperuricemic patients with chronic heart failure: results from 2 placebo-controlled studies. Circulation (2002) 2.71
Associations of body fat and its changes over time with quality of life and prospective mortality in hemodialysis patients. Am J Clin Nutr (2006) 2.67
Assessing and grading congestion in acute heart failure: a scientific statement from the acute heart failure committee of the heart failure association of the European Society of Cardiology and endorsed by the European Society of Intensive Care Medicine. Eur J Heart Fail (2010) 2.64
The obesity paradox and mortality associated with surrogates of body size and muscle mass in patients receiving hemodialysis. Mayo Clin Proc (2010) 2.55
A single dose of erythropoietin in ST-elevation myocardial infarction. Eur Heart J (2010) 2.52
Ethical guidelines for authorship and publishing in the Journal of Cachexia, Sarcopenia and Muscle. J Cachexia Sarcopenia Muscle (2010) 2.49
Prognostic utility of growth differentiation factor-15 in patients with chronic heart failure. J Am Coll Cardiol (2007) 2.46
Sarcopenia with limited mobility: an international consensus. J Am Med Dir Assoc (2011) 2.34
Cardiac inflammation contributes to changes in the extracellular matrix in patients with heart failure and normal ejection fraction. Circ Heart Fail (2010) 2.30
Impaired insulin sensitivity as an independent risk factor for mortality in patients with stable chronic heart failure. J Am Coll Cardiol (2005) 2.28
Mid-region pro-hormone markers for diagnosis and prognosis in acute dyspnea: results from the BACH (Biomarkers in Acute Heart Failure) trial. J Am Coll Cardiol (2010) 2.25
Prediction of mode of death in heart failure: the Seattle Heart Failure Model. Circulation (2007) 2.22
Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction: Data From SENIORS (Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors With Heart Failure). J Am Coll Cardiol (2009) 2.20
Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial. Eur Heart J (2011) 2.14
The relationship between cholesterol and survival in patients with chronic heart failure. J Am Coll Cardiol (2003) 2.12
Ursodeoxycholic acid in patients with chronic heart failure: a double-blind, randomized, placebo-controlled, crossover trial. J Am Coll Cardiol (2012) 2.11
Impact of atrial fibrillation on the accuracy of oscillometric blood pressure monitoring. Hypertension (2013) 2.10
Cachexia as a major underestimated and unmet medical need: facts and numbers. J Cachexia Sarcopenia Muscle (2010) 2.04
Anabolic deficiency in men with chronic heart failure: prevalence and detrimental impact on survival. Circulation (2006) 2.00
Lack of evidence of increased mortality among patients with atrial fibrillation taking digoxin: findings from post hoc propensity-matched analysis of the AFFIRM trial. Eur Heart J (2013) 1.99
Suppression of endothelial progenitor cells in human coronary artery disease by the endogenous nitric oxide synthase inhibitor asymmetric dimethylarginine. J Am Coll Cardiol (2005) 1.99
Effect of darbepoetin alfa on exercise tolerance in anemic patients with symptomatic chronic heart failure: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol (2007) 1.92
An overview of sarcopenia: facts and numbers on prevalence and clinical impact. J Cachexia Sarcopenia Muscle (2010) 1.89
Inverse relation of body weight and weight change with mortality and morbidity in patients with type 2 diabetes and cardiovascular co-morbidity: an analysis of the PROactive study population. Int J Cardiol (2011) 1.89
Palliative care in heart failure: a position statement from the palliative care workshop of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail (2009) 1.86
Weight loss and mortality risk in patients with chronic heart failure in the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programme. Eur Heart J (2008) 1.84
Anemia and inflammation in COPD. Chest (2005) 1.83
Risk factor paradox in wasting diseases. Curr Opin Clin Nutr Metab Care (2007) 1.82
Cardiac deletion of the Coxsackievirus-adenovirus receptor abolishes Coxsackievirus B3 infection and prevents myocarditis in vivo. J Am Coll Cardiol (2009) 1.81
Renin inhibition improves cardiac function and remodeling after myocardial infarction independent of blood pressure. Hypertension (2008) 1.78
Inflammatory mediators in chronic heart failure: an overview. Heart (2004) 1.78
Secretory sphingomyelinase is upregulated in chronic heart failure: a second messenger system of immune activation relates to body composition, muscular functional capacity, and peripheral blood flow. Eur Heart J (2007) 1.75
Uric acid-lowering treatment with benzbromarone in patients with heart failure: a double-blind placebo-controlled crossover preliminary study. Circ Heart Fail (2009) 1.73
Angiotensin II type 2 receptor stimulation: a novel option of therapeutic interference with the renin-angiotensin system in myocardial infarction? Circulation (2008) 1.72
Assessment of survival in patients with primary pulmonary hypertension: importance of cardiopulmonary exercise testing. Circulation (2002) 1.70
Prevalence, incidence and clinical impact of cachexia: facts and numbers-update 2014. J Cachexia Sarcopenia Muscle (2014) 1.68
Enhancement of the endothelial NO synthase attenuates experimental diastolic heart failure. Basic Res Cardiol (2009) 1.62
Exercise training in heart failure: from theory to practice. A consensus document of the Heart Failure Association and the European Association for Cardiovascular Prevention and Rehabilitation. Eur J Heart Fail (2011) 1.61
Inflammation as a therapeutic target in heart failure? A scientific statement from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail (2009) 1.61
Age-dependent impairment of endothelial progenitor cells is corrected by growth-hormone-mediated increase of insulin-like growth-factor-1. Circ Res (2007) 1.61
Anemia and iron deficiency in heart failure: mechanisms and therapeutic approaches. Nat Rev Cardiol (2011) 1.59
Left ventricular dysfunction induced by nonsevere idiopathic pulmonary arterial hypertension: a pressure-volume relationship study. Am J Respir Crit Care Med (2012) 1.59
Prognostic impact of plasma N-terminal pro-brain natriuretic peptide in severe chronic congestive heart failure: a substudy of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) trial. Circulation (2004) 1.59
Anorexia in chronic obstructive pulmonary disease--association to cachexia and hormonal derangement. Int J Cardiol (2006) 1.58
Neurohormonal activation and the chronic heart failure syndrome in adults with congenital heart disease. Circulation (2002) 1.58
Development of diastolic heart failure in a 6-year follow-up study in patients after acute myocarditis. Heart (2010) 1.57
Effect of intravenous iron sucrose on exercise tolerance in anemic and nonanemic patients with symptomatic chronic heart failure and iron deficiency FERRIC-HF: a randomized, controlled, observer-blinded trial. J Am Coll Cardiol (2008) 1.57
Differential interaction of clinical characteristics with key functional parameters in heart failure with preserved ejection fraction--results of the Aldo-DHF trial. Int J Cardiol (2013) 1.56
Beyond the cardiorenal anaemia syndrome: recognizing the role of iron deficiency. Eur J Heart Fail (2012) 1.56
Absence of obesity paradox in patients with chronic heart failure and diabetes mellitus: a propensity-matched study. Eur J Heart Fail (2010) 1.55
Vascular-protective effects of high-density lipoprotein include the downregulation of the angiotensin II type 1 receptor. Hypertension (2009) 1.54
Body mass and survival in patients with chronic heart failure without cachexia: the importance of obesity. J Card Fail (2003) 1.54
Are hospitalized or ambulatory patients with heart failure treated in accordance with European Society of Cardiology guidelines? Evidence from 12,440 patients of the ESC Heart Failure Long-Term Registry. Eur J Heart Fail (2013) 1.53